Exelixis Inc (EXEL.OQ)
EXEL.OQ on NASDAQ Stock Exchange Global Select Market
5.07USD
10:54am EDT
5.07USD
10:54am EDT
Price Change (% chg)
$0.00 (+0.00%)
$0.00 (+0.00%)
Prev Close
$5.07
$5.07
Open
$5.09
$5.09
Day's High
$5.17
$5.17
Day's Low
$5.01
$5.01
Volume
64,966
64,966
Avg. Vol
411,847
411,847
52-wk High
$6.30
$6.30
52-wk Low
$4.20
$4.20
About
Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is... (more)
Overall
| Beta: | 1.93 |
| Market Cap (Mil.): | $930.04 |
| Shares Outstanding (Mil.): | 183.80 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| EXEL.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 47.13 | 37.76 |
| EPS (TTM): | -0.97 | -- | -- |
| ROI: | -36.26 | -2.58 | 18.76 |
| ROE: | -85.86 | -2.66 | 19.59 |
Competitors
| Price | Change | |
|---|---|---|
| AstraZeneca plc (AZN.L) | 3,315.50p | -19.50 |
| Pfizer Inc. (PFE.N) | $29.19 | -0.04 |
| ArQule, Inc. (ARQL.OQ) | $2.69 | +0.02 |
| GlaxoSmithKline plc (GSK.L) | 1,706.50p | +22.50 |
| Algeta ASA (ALGETA.OL) | kr244.60 | +3.00 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$58.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

